CD274 and triple-negative breast carcinoma: Indeed, the only targeted therapy currently approved for triple-negative breast cancers is pembrolizumab (an antibody against programmed death-receptor PD-1 that provides dual ligand blockade of programmed death-ligands PD-L1 and PD-L2).